Skip to content
    RCUS
    Earnings call· Jun 2026(Q2 FY26)

    Arcus Biosciences Q2 FY26 earnings call RCUS

    Aug 5, 2026 Source

    Executive summary

    Arcus Biosciences, Inc. Q2 FY26 — Casdatifan Advances Across RCC Treatment Lines with Key Data Readouts Expected

    Arcus Biosciences is rapidly advancing its oncology and immunology pipeline, with a primary focus on casdatifan, its next-generation HIF-2-alpha inhibitor, which is positioned to become a foundational therapy across all lines of clear cell RCC treatment. The company is leveraging strategic collaborations to expand its development program efficiently, while also progressing a broad immunology portfolio and preparing for key data readouts for casdatifan and quemliclustat. Strong financial positioning supports these initiatives, aiming for significant value creation.

    Highlights

    5

    • Casdatifan's PEAK-1 Phase III trial for second-line clear cell RCC is on track to complete enrollment by year-end 2026.

    • Multiple new clinical trial collaborations for casdatifan were initiated in the last 2 months, including with BMS, Summit Therapeutics, and AVEO, allowing Arcus to retain full rights.

    • AB102, an oral MRGPRX2 antagonist, is entering human dosing this month, with PK profile data expected in Q4 FY26.

    • Cash and investments of $775 million as of June 30, 2026, provide a runway into at least H2 2028.

    • Full-year 2026 GAAP revenue is expected to be $65 million to $75 million.

    Concerns

    3

    • Merck's LITESPARK-012 study failure was noted, though framed as creating an opportunity for Arcus by removing a key competitor in the frontline.

    • Collaboration revenue is expected to decrease due to the wind-down of the domvanalimab program.

    • Belzutifan has failed to show statistically significant benefit in OS in 3 out of 3 registrational trials, highlighting a potential challenge for HIF-2 inhibitors if not sufficiently potent.

    Guidance & targets

    13
    CategoryTargetConfidence
    PEAK-1 Phase III enrollment completion
    by the end of this year
    high materiality
    High
    PEAK-20 Phase III trial initiation
    by the end of 2026
    high materiality
    High
    AB102 human dosing initiation
    this month
    medium materiality
    High
    AB102 PK profile data readout
    in the fourth quarter
    medium materiality
    High
    Oral selective TNF receptor 1 inhibitor clinical entry
    early 2027
    medium materiality
    High
    PRISM-1 Phase III study data readout
    in the first half of next year
    high materiality
    High
    ARC-20 casdatifan data readouts
    in an investor forum in October prior to ESMO
    high materiality
    High
    Full-year 2026 GAAP revenue
    $65 million to $75 million
    medium materiality
    High
    Cash and investments balance
    approximately $600 million
    high materiality
    High
    Cash runway
    into at least the second half of 2028
    high materiality
    High
    R&D spend trajectory
    meaningful decrease in overall R&D spend in 2026 and 2027 relative to 2025
    medium materiality
    High
    Portfolio spend allocation
    more than 80% of our portfolio spend to be directed toward casdatifan development
    medium materiality
    High
    AB102 proof-of-concept study in CSU
    mid-2027
    medium materiality
    High

    Operational metrics

    19
    Cash and investments balance
    $775 milliondown from $876 million at Q1 FY26 end
    Q2 FY26

    Provides runway into at least the second half of 2028.

    GAAP Revenue
    $41 million
    Q2 FY26

    Primarily driven by collaboration agreements.

    R&D expenses (net of reimbursements)
    $113 million
    Q2 FY26

    Expected to decrease meaningfully in 2026 and 2027 due to wind-down of domvanalimab trials and reduced spend on quemliclustat.

    G&A expenses
    $24 million
    Q2 FY26
    Non-cash stock-based compensation
    $15 million
    Q2 FY26
    Casdatifan peak sales opportunity
    $5 billion to $10 billion
    Peak

    Driven by its potential as a backbone therapy across all lines of kidney cancer treatment.

    RCC drugs market size
    $13 billion
    by 2030

    Expected growth in the overall RCC drug market.

    Quemliclustat commercial opportunity
    multi-billion-dollar
    future

    Opportunity in frontline pancreatic cancer if PRISM-1 is successful.

    Ipi-nivo primary progression rate
    approximately 20%
    current

    This is a key limitation that casdatifan aims to improve upon.

    Cas + zim primary progression rate
    7%vs 30% for anti-PD-1 monotherapy
    current

    From ARC-20 cohort, completed enrollment at beginning of this year.

    Ipi-nivo market share
    about 30%
    current

    Casdatifan has the potential to increase this to 50% or more.

    Cabozantinib monotherapy market share
    roughly 40%
    current

    Represents the current standard of care in the second line.

    Lenvatinib toxicity profile (all-grade cardiac dysfunction)
    7%vs 1% for cabo
    LITESPARK-011

    Compared to cabozantinib in a randomized study.

    Lenvatinib toxicity profile (Grade 3 or higher cardiac dysfunction)
    5%vs 0.5% for cabo
    LITESPARK-011

    A tenfold difference compared to cabozantinib in a randomized study.

    Patients remaining on casdatifan treatment
    approximately 25%
    beyond 2 years

    Demonstrates the long-term tail effect contributing to peak sales opportunity.

    HIF-2 as a driver in RCC
    85 to 90-plus percent
    current

    Highlights the strong rationale for HIF-2 inhibition in this cancer type.

    Median PFS for ipi-nivo
    12.4 months
    CheckMate 214

    Used as a benchmark for comparison with casdatifan regimens.

    Median PFS for belzutifan monotherapy
    5.6 monthsabout the same as everolimus
    LITESPARK-005

    Used to illustrate the impact of HIF-2 inhibition durability.

    OS for cabozantinib
    just over 21 months
    current

    Used as a benchmark for potential OS advantage of cas+cabo.

    Industry KPIs

    4
    MetricValueDetails
    Pipeline read out calendarARC-20 data readouts
    Peak long term sales guidance$5 billion to $10 billionUSD
    Therapeutic drug market shareabout 30%%
    Clinical trial efficacy safety data7%%

    Product announcements

    1
    ProductTypeDetails
    AB102launch

    Deals & partnerships

    5
    BMSEvaluate casdatifan in combination with pumita (bispecific anti-PD-L1/VEGF antibody) in the first-line setting.

    Announced in June. BMS will evaluate two cas + pumita-based combinations in its platform study, ROSETTA RCC-208.

    Summit TherapeuticsEvaluate casdatifan in combination with ivo (bispecific anti-PD-1/VEGF antibody) in the first-line setting.

    Announced in July. Arcus will conduct this study in a first-line cohort as part of ARC-20. Expected to begin by end of year.

    AVEOCombine casdatifan with tivo in advanced belzutifan-experienced patients.

    Announced in July. This study will enable a planned late-line registrational study evaluating cas-tivo in both HIF-2 inhibitor-experienced and naive patients.

    TaihoHolds commercial rights to casdatifan outside of Japan and certain other Asian territories.

    Arcus owns all commercial rights to casdatifan outside these territories.

    GileadWind-down of domvanalimab program; holds an option on the TNF program.

    Reduced activity under this collaboration is impacting revenue.

    Risks & headwinds

    4
    Competition in frontline clear cell RCCcurrent

    Merck's LITESPARK-012 study failure

    Mitigation: Casdatifan now has no competition in the frontline space as a HIF-2-alpha inhibitor, creating a clear path to consolidate the fragmented market.

    Lack of overall survival benefit for belzutifancurrent

    failed to show statistically significant benefit in OS in 3 out of 3 registrational trials

    Mitigation: Arcus aims to differentiate casdatifan with early look at OS data from late-line monotherapy cohort (28 months median follow-up) and potential OS advantage in second-line cas+cabo.

    Toxicity profile of Lenvatinibcurrent

    all-grade cardiac dysfunction was 7% for belz-lenva versus just 1% for cabo; Grade 3 or higher cardiac dysfunction was 5% for belz-lenva versus 0.5% for cabo

    Mitigation: Arcus is combining casdatifan with cabozantinib, which has better tolerability, expecting cas+cabo to be preferred based on efficacy and safety.

    Decreased collaboration revenueongoing

    Future operating results are expected to reflect lower collaboration revenue

    Mitigation: Due to reduced activity under the Gilead collaboration, driven by the wind-down of the domvanalimab program. Offset by new capital-efficient collaborations.

    What to watch in Q3 FY26

    5

    PEAK-1 Phase III enrollment completion

    by year-end 2026
    Currenton track
    Targetcompleted

    Why it matters

    Completion of enrollment is a key milestone for the registrational study of casdatifan in second-line RCC, impacting its path to market.

    PEAK-1, evaluating cas plus cabo, the gold standard of care in second-line clear cell RCC, has tremendous investigator enthusiasm, and we remain on track to complete enrollment by the end of this year.

    Q&A highlights

    4

    What are the success metrics for the upcoming data, and which parts of the dataset should investors prioritize?

    Terry Rosen outlined that overall success would be convincing investors that casdatifan will become the backbone standard in RCC across all lines. He highlighted the frontline opportunity as huge ($5B+ market) with no competition. For the frontline cas+ipi+nivo data, safety and primary progression rate are key. For cas+zim, ORR data with 11 months follow-up and PFS curve shape will be informative. For second-line cas+cabo, better PFS than belz-lenva and potential OS advantage over cabo are targets. For late-line monotherapy, 28 months follow-up will provide an early look at OS, demonstrating HIF-2's impact on durability.

    “So at the highest level, I think we want people to walk away and believe they will walk away knowing that casdatifan is going to become the backbone standard in RCC across all lines of therapy.”

    asked by Salim Syed · answered by Terry Rosen

    2 min read6 chapters

    Detailed Narrative

    01

    Casdatifan's Strategic Positioning in RCC

    Arcus is positioning casdatifan as a foundational therapy across all lines of clear cell RCC treatment, aiming for a $5 billion to $10 billion peak sales opportunity. The company emphasizes casdatifan's superior efficacy profile over belzutifan and its potential to become the common denominator in the fragmented frontline market, especially after Merck's LITESPARK-012 study failure removed a key competitor. The development strategy is designed to provide flexibility to physicians with HIF-2-alpha inhibitor enhanced options.

    02

    Clinical Development Expansion and Collaborations

    Arcus is rapidly expanding casdatifan's development program through its ARC-20 platform study and clinical collaborations, allowing it to retain full rights. Recent partnerships include BMS (cas + pumita), Summit Therapeutics (cas + ivo), and AVEO (cas + tivo). These collaborations enable investigation of mechanistic combinations in first-line and late-line settings, leveraging bispecific anti-PD-1/VEGF antibodies and existing TKIs.

    03

    Scientific Basis and Differentiation of Casdatifan

    Recent research published in Nature highlights casdatifan's deep and sustained suppression of erythropoietin, correlating with higher response rates and longer progression-free survival. Management asserts that casdatifan's more robust and durable HIF-2-alpha inhibition may provide better outcomes for patients with prior TKI exposure, unlike belzutifan, which showed an inverse correlation with prior TKI therapies. This scientific differentiation underpins confidence in casdatifan's potential.

    04

    Immunology Portfolio Advancement

    Arcus is building a broad immunology portfolio with several programs approaching clinical development, including AB102 (MRGPRX2 antagonist) entering human dosing this month, and an oral selective TNF receptor 1 inhibitor expected in early 2027. This portfolio targets validated and emerging mechanisms in autoimmune and allergic diseases, offering strategic optionality and addressing high unmet needs in large markets.

    05

    Quemliclustat in Pancreatic Cancer

    The Phase III PRISM-1 study of quemliclustat and chemotherapy in frontline pancreatic cancer is on track for initial data readout in the first half of next year. Management sees a multi-billion-dollar commercial opportunity for quemliclustat as a well-tolerated, all-comer, first-line option that can substantially enhance the benefit of immunogenic chemotherapy.

    06

    Financial Strength and Capital Efficiency

    Arcus reported $775 million in cash and investments as of June 30, 2026, with a projected runway into at least the second half of 2028. The company emphasizes capital efficiency, with new collaboration agreements structured to advance programs without significant demands on its own resources. R&D spend is expected to decrease in 2026 and 2027, with over 80% of the portfolio spend directed towards casdatifan development by 2027.

    AI-generated summary of the company’s earnings call. Not investment advice.